Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parkinson's disease: managing symptoms and preserving function

P J Sweeney1

  • 1Department of Neurology, Cleveland Clinic Foundation, OH, USA.

Geriatrics
|September 1, 1995
PubMed
Summary

This summary discusses Parkinson's disease (PD) drug therapies, including neuroprotective and symptomatic strategies. While selegiline may delay symptomatic treatment in early PD, its effect on disease progression is debated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pronase (EC 3.4.24.4).

Methods in molecular biology (Clifton, N.J.)·2008
Same author

Proteolytic enzymes for peptide production.

Methods in molecular biology (Clifton, N.J.)·2008
Same author

Proteinase K (EC 3.4.21.14).

Methods in molecular biology (Clifton, N.J.)·2008
Same author

Aminopeptidases: aminopeptidase M (EC 3.4.11.2), pyroglutamate aminopeptidase (EC 3.4.19.3), and prolidase (EC 3.4.13.9).

Methods in molecular biology (Clifton, N.J.)·2008
Same author

A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors.

Neurology·2003
Same author

Metastatic adenocarcinoma to a pituitary adenoma.

Annals of diagnostic pathology·2001

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Parkinson's disease (PD) management involves neuroprotective and symptomatic drug therapies.
  • The optimal timing for initiating symptomatic treatment is patient-dependent, based on symptom severity.

Purpose of the Study:

  • To review current drug therapy strategies for Parkinson's disease.
  • To discuss the role of specific medications like selegiline, anticholinergics, and levodopa.
  • To highlight ongoing research in surgical interventions and transplantation therapies.

Main Methods:

  • Literature review of Parkinson's disease pharmacological and therapeutic approaches.
  • Analysis of treatment strategies based on disease stage and symptom presentation.

Main Results:

  • Selegiline's potential to delay symptomatic treatment in early PD is noted, though its disease-modifying effect is uncertain.
  • Anticholinergics are effective for early tremor, while controlled-release levodopa is an option when levodopa is initiated.
  • Dopamine agonists are increasingly used as adjunctive therapies.

Conclusions:

  • Treatment decisions for Parkinson's disease are individualized based on symptom burden.
  • A range of pharmacological options exist, with ongoing research into novel therapies like transplantation.

Related Experiment Videos